Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$1.13 USD
-0.02 (-1.74%)
Updated Jul 25, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Clearside Biomedical, Inc. [CLSD]
Reports for Purchase
Showing records 121 - 140 ( 274 total )
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update - Remains a Top Pick With Multiple Value Drivers During 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX/Wet-AMD: Phase 1/2a Cohort 1 Dosed; Initial Safety Data in Mid:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
CLS-AX Phase 1/2 Study Progresses - Safety Data Expected in Mid-2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Angiogenesis 2021 Highlights CLS-AX?s Extended Durability Potential
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Presentations on SCS Microinjector? at Macula Society Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Suprachoroidal Pipeline Off to a Super Start; Multiple Catalysts in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
First Patients Enrolled in Phase 1/2 Wet AMD Study - Data by Mid-2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Glass Half Full: Our Top Biotech & Healthcare Ideas for 2021
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Janssen''s Hemera Deal Further Validates Clearside''s Platform Value
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Catalyst Rich 2021 Supports Our Positive Outlook
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Steady Progress Impresses with Major Data Updates in 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Company: Clearside Biomedical, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Key Takeaways From Our Mgmt Talk Series
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z